Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sophia GeneticsSOPH +15.25%70 EV-to-EBITDA is -9.48 as of Aug. 09, 2026. GuruFocus rates SOPH with a GF Score™ of 70/100 and a GF Value™ of $5.09 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 512 Healthcare Providers & Services companies, Sophia Genetics ranks worse than 195312.3% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sophia Genetics's enterprise value is $598.48 Mil.
Sophia Genetics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-63.16 Mil. Therefore, Sophia Genetics's EV-to-EBITDA for today is -9.48.
The historical rank and industry rank for Sophia Genetics's EV-to-EBITDA or its related term are showing as below:
SOPH'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -22.95 Med: -3.06 Max: 0.93
Current: -9.48
During the past 8 years, the highest EV-to-EBITDA of Sophia Genetics was 0.93. The lowest was -22.95. And the median was -3.06.
SOPH's EV-to-EBITDA is ranked worse than 100% of 512
companies
in the Healthcare Providers & Services industry
Industry Median: 10.965
vs SOPH: -9.48
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sophia Genetics's PE Ratio (TTM) for today is calculated as:
Sophia Genetics's share price for today is $7.68.
Sophia Genetics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.150.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Sophia Genetics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Sophia Genetics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sophia Genetics EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sophia Genetics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sophia Genetics's EV-to-EBITDA falls into.
Sophia Genetics's current Enterprise Value is $598.48 Mil.
Sophia Genetics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-63.16 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sophia Genetics (SOPH) has a EV-to-EBITDA of -9.48 as of Aug. 09, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sophia Genetics. According to the industry distribution chart, Sophia Genetics ranks #999999 out of 512 companies in the Healthcare Providers & Services industry.
Is Sophia Genetics' EV-to-EBITDA too high?
Sophia Genetics' current EV-to-EBITDA is -9.48. Based on the distribution chart, Sophia Genetics ranks #999999 out of 512 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Sophia Genetics has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sophia Genetics' EV-to-EBITDA compare to EVH and NRC?
According to the Healthcare Providers & Services industry distribution chart, Sophia Genetics ranks #999999 out of 512 companies for EV-to-EBITDA. This places Sophia Genetics in the lower half of its industry. The industry median EV-to-EBITDA is 10.97. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.97, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sophia Genetics. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sophia Genetics's current EV-to-EBITDA is -9.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sophia Genetics stock overvalued right now?
Based on GuruFocus' analysis, Sophia Genetics (SOPH) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.09, compared to a current price of $7.68 — trading 50.9% above its estimated fair value. The current EV-to-EBITDA is -9.48. Sophia Genetics' overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Sophia Genetics (SOPH), the current EV-to-EBITDA is -9.48 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sophia Genetics (SOPH) Overvalued in 2026?
Based on GuruFocus' analysis, Sophia Genetics stock appears to be overvalued.
The current stock price of $7.68 is trading 50.9% above its estimated GF Value™ of $5.09.
GuruFocus considers Sophia Genetics to be Significantly Overvalued.
Key valuation signals for SOPH:
EV-to-EBITDA: -9.48
GF Value™: $5.09 vs. price of $7.68 (50.9% above fair value)
No single metric tells the full story. See the SOPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
70GF Score
Get the complete analysis for SOPH
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SOPH has been successfully added to your 
